Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Watanabe T, Drucker DJ, and Wagtmann N
Fewer Disease Flares With GLP-1 Therapy In a retrospective study led by Shreya Sakthivel, Chief Resident of Internal Medicine at Anne Arundel Medical Center, investigators found that RA patients receiving disease-modifying antirheumatic drugs (DMARDs) who also took GLP-1 receptor agonists or SGLT2 inhibitors experienced fewer disease flares than those on DMARDs alone
GLP-1 RAs exhibit a broad range of effects on the cardiovascular system that are independent of changes in blood glucose
Trials differ in how they handle participants who discontinue
Retatrutide Retatrutide represents the most advanced triple agonist aiming GLP-1, GIP, and GCG simultaneously
Regular dental care and simple preventive steps can help reduce the risk and keep your teeth healthy throughout treatment